$ cat ./records/gates-funded-path-hpv-vaccine-study-in-india-suspended-over-conse-2010.txt
Gates-Funded PATH HPV Vaccine Study in India Suspended Over Consent Violations
[RECORD.TXT] · cat --full
In 2009–2010, PATH — with funding from the Gates Foundation — ran a large HPV-vaccine 'demonstration' study in the Indian states of Andhra Pradesh and Gujarat, giving Merck's Gardasil or GSK's Cervarix to roughly 24,000 girls aged 10–14. India's Council of Medical Research suspended the project in April 2010 after the reported deaths of seven participants. Government and state investigations concluded the deaths were not caused by the vaccines (causes included drowning, snakebite, pesticide poisoning, and malaria), but a parliamentary standing committee found serious ethical irregularities — including improperly obtained consent (often signed by hostel wardens for tribal girls) and inadequate monitoring of adverse events. The case became a touchstone in debates over the ethics of foreign-funded clinical research in low-income settings.
Source: https://www.science.org/content/article/indian-parliament-comes-down-hard-cervical-cancer-trial
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
A 2010 TED Talk Remark on Vaccines and Population Growth Is Twisted Into a Lasting Conspiracy Theory
Next →
Gates Foundation backs digital banking for the poor
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.